Objective. Current validated cardiovascular (CV) risk estimates were developed in populations with relatively stable levels of inflammation, whereas patients with rheumatoid arthritis (RA) routinely experience significant changes in inflammation. This study was undertaken to test whether changes in inflammation affect estimated CV risk as measured using validated population-based risk calculators.
Objective. Current validated cardiovascular (CV) risk estimates were developed in populations with relatively stable levels of inflammation, whereas patients with rheumatoid arthritis (RA) routinely experience significant changes in inflammation. This study was undertaken to test whether changes in inflammation affect estimated CV risk as measured using validated population-based risk calculators.
Methods. Participants in a prospective RA cohort who experienced a decrease or an increase of ≥10 mg/liter in the C-reactive protein (CRP) level at 2 consecutive time points 1 year apart (CRP decrease group and CRP increase group, respectively) were included in this study. We estimated 10-year CV risk using the following calculators: Framingham Risk Score, 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score, Reynolds Risk Score (RRS), and QRISK2. Of these calculators, only the RRS includes a variable addressing the CRP level. Paired t-tests were performed to compare risk scores at baseline and 1-year follow-up. We calculated the correlations between the changes in risk scores and changes in pro-B-type natriuretic peptide (pro BNP), a surrogate marker of CV risk.
Results. One hundred eighty RA patients were included in the study (mean age 57.8 years, 84% female, 80% seropositive). Of the calculators studied, only the RRS was sensitive to changes in inflammation; an increase in inflammation was associated with increased estimated CV risk (P < 0.0001), and only the RRS was correlated with changes in proBNP (r = 0.17, P = 0.03).
Conclusion. Our data showed no significant change in CV risk estimated using validated general population CV risk calculators except for the RRS. These findings suggest that CV risk may be modulated by changes in inflammation in RA, which is not typically considered when using existing CV risk calculators. Cardiovascular (CV) risk calculators assist clinicians in estimating a patient's risk of experiencing a CV event. The majority of these risk estimation tools, such as the Framingham Risk Score (FRS), the 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score (2013 ACC/AHA), the Reynolds Risk Score (RRS), and the QRISK2, were developed for the general population, where inflammation tends to be stable. Inflammation is an independent risk factor for CV risk in the general population and has an even larger impact in rheumatoid arthritis (RA), where the magnitude of inflammation is higher (1) (2) (3) . Prior studies using carotid intima-media thickness as a marker for CV risk have shown that both the magnitude and the duration of exposure to elevated inflammation are associated with increased CV risk (4, 5) . Additionally, in RA the level of inflammation can vary as a result of flares and treatment changes.
Previous studies have demonstrated that a change in inflammation in RA corresponds to changes in traditional CV risk factors, such as lipid levels (6) . It remains to be determined whether the changes associated with inflammation, such as the changes in lipids, impact estimates of CV risk obtained using validated CV risk calculators developed for the general population. The objective of this study was to examine the effect of changes in inflammation in RA on estimated CV risk as calculated using validated general population risk calculators. Since the true CV risk was not known, we used levels of pro-B-type natriuretic peptide (proBNP) as a surrogate marker of CV risk. ProBNP is a risk factor for increased CV risk in subjects with and those without established coronary artery disease (7) .
PATIENTS AND METHODS
Study population. The present investigation was conducted within the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) (8), a prospective observational cohort study. All patients in the BRASS cohort are age 18 years or older and have rheumatologist-diagnosed RA. Participants in the BRASS undergo baseline assessment that includes recording of demographic characteristics, lifestyle factors, medication use, CV risk factors, and CV events, and have annual visits for information update. High-sensitivity C-reactive protein (CRP), a marker of inflammation, is measured in all participants annually. We included participants who experienced a decrease or an increase of ≥10 mg/liter in the CRP level at 2 consecutive time points 1 year apart (CRP decrease group and CRP increase group, respectively) and had blood samples available for analysis. All aspects of this study were approved by the Partners Healthcare Institutional Review Board, and all participants provided written informed consent.
Biochemical analysis. All biomarkers were measured at the Clinical Chemistry Laboratory of Children's Hospital (Boston, MA). Plasma high-sensitivity CRP was measured using a standard immunoturbidimetric assay on a Roche P Modular system (9) . ProBNP was measured using a quantitative sandwich enzyme immunoassay (Roche E Modular system). Total cholesterol, high-density lipoprotein (HDL) cholesterol, and hemoglobin A 1c (HbA 1c ) measurements were performed according to standardized methods (10, 11) .
Other variables. In the baseline and annual follow-up questionnaires in the BRASS, information on age, sex, race, smoking status, medication use (including hypertension medications), and CV risk factors (including body mass index, CRP level, blood cholesterol levels, history of chronic diseases such as diabetes, atrial fibrillation, chronic kidney disease, and RA, and family history of premature myocardial infarction) was collected. Data on blood pressure and HbA 1c levels were obtained from structured electronic medical record data. Since this study was focused on CV disease (CVD) risk prediction, we additionally performed chart reviews to assess and exclude patients who took statins or had evidence of CVD before or during the study period.
Statistical analysis. We calculated 10-year CV risk using 4 externally validated general population CV risk calculators: the FRS, the 2013 ACC/AHA, the RRS, and the QRISK2. We applied the inclusion/exclusion criteria of each calculator to the cohorts (for the FRS, target age group 30-74 years; for the 2013 ACC/AHA, target age group 40-79 years, exclusion criteria history of myocardial infarction, stroke, congestive heart failure, percutaneous coronary intervention, coronary artery bypass graft, or atrial fibrillation; for the RRS in women, target age group 45-80 years, exclusion criteria history of CVD or cancer; for the RRS in men, target age group 50-80 years, exclusion criteria history of CVD, diabetes mellitus, or cancer; for the QRISK2, target age group 35-74 years, exclusion criteria history of CVD or cerebrovascular disease, or statin treatment at baseline). This resulted in a slightly different population tested with each risk calculator (in the overall study population, n = 148 for the FRS, 147 for the 2013 ACC/AHA, 164 for the RRS, and 172 for the QRISK2; in the CRP decrease group, n = 68 for the FRS, 65 for the 2013 ACC/AHA, 70 for the RRS, and 76 for the QRISK2; in the CRP increase group, n = 80 for the FRS, 82 for the 2013 ACC/AHA, 94 for the RRS, and 96 for the QRISK2).
The published equations for the calculators (12-16) were used to generate the estimated CV risk. For the primary analysis, we used paired t-tests to compare 10-year estimated CV risk at baseline and 1-year follow-up among participants in the CRP decrease and increase groups. In addition, we determined the correlations between changes in estimated CV risk and changes in proBNP levels, using Pearson's correlation test. Both estimated CV risks and proBNP levels were log transformed because of non-normal distribution.
In the sensitivity analyses, we controlled for potential changes in CV risk estimation not impacted by inflammation, i.e., age. Thus, we calculated the estimated CV risks using the same age at both baseline and 1-year follow-up in order to control for the influence of age on CV risk. Calculations controlling for age were performed for both the primary and secondary analyses. For all statistical analyses, 2-sided P values less than 0.05 were considered significant. All data analyses were performed using SAS 9.4. * Data were missing on 20 patients for anti-cyclic citrullinated peptide (anti-CCP) positivity, 131 patients for rheumatoid factor (RF) positivity, 1 patient for body mass index (BMI), and 8 patients for 28-joint Disease Activity Score (DAS28). Except where indicated otherwise, values are the number (%). RA = rheumatoid arthritis; DMARD = disease-modifying antirheumatic drug; TNF = tumor necrosis factor; CRP = C-reactive protein; IQR = interquartile range; proBNP = pro-B-type natriuretic peptide.
RESULTS
A total of 180 RA patients were included in the study, of whom 79 experienced a reduction in the CRP level and 101 had an increase in the CRP level. Baseline characteristics of the patients are shown in Table 1 . In the overall study population, the mean age was 57.8 years and the mean duration of RA was 18.2 years; 84% were female and 80% were seropositive. The mean 28-joint Disease Activity Score (17) was 4.0, indicating moderate disease activity. Sixty-eight percent of the patients were receiving treatment with a nonbiologic disease-modifying antirheumatic drug (DMARD), and 52% were receiving methotrexate. Fiftyfour percent were receiving a biologic DMARD (a tumor necrosis factor inhibitor in 49%). In the CRP decrease group, the median CRP level at baseline was 28 Table 2 .
Among participants experiencing a decrease in CRP level, we observed significant changes in CV risk only as calculated using the RRS. With this instrument the estimated 10-year CV risk was 2.57% at baseline and decreased to 1.84% at follow-up (P < 0.0001). Among participants with an increase in CRP level, we observed a significant increase in estimated CV risk using the RRS, from 2.86% at baseline to 4.42% at 1-year follow-up (P < 0.0001). No significant changes were observed with the FRS (P = 0.77 in the CRP decrease group; P = 0.58 in the increase group) or the 2013 ACC/AHA (P = 0.19 in the CRP decrease group; P = 0.09 in the increase group) ( Table 3 ). The QRISK2 demonstrated a change in the 10-year CV risk estimates, with estimated risk increasing significantly in both groups regardless of the direction of change in the CRP level (from 6.54% to 6.69% [P = 0.005] in the CRP decrease group; from 10.52% to 10.90% [P = 0.01] in the CRP increase group). The significant changes in estimated CV risk observed using the QRISK2 were no longer present in the sensitivity analysis when age was kept constant. In contrast, the significant changes in estimated CV risk using the RRS remained for both groups, even after controlling for age (Table 4 ).
In the secondary analysis, we investigated the correlation between change in estimated CV risk with each CV risk calculator and change in proBNP level. Among participants in the CRP decrease group, the median proBNP level decreased from 83.64 pg/ml to 75.85 pg/ ml; in the CRP increase group, the median proBNP level increased from 86.81 pg/ml to 111.60 pg/ml. Only the changes in RRS CV risk estimate were significantly correlated with changes in proBNP level (r = 0.17, P = 0.03) ( Table 5) . Similar results were observed in the sensitivity analysis (Table 6 ).
DISCUSSION
When comparing across general population-based CV risk calculators, changes in inflammation were associated with changes in estimated CV risk calculated using the RRS, in which CRP is one of the variables assessed. This finding was expected since CRP is included in the RRS. However, the increase in CV risk associated with the RRS was also significantly correlated with evidence of increased subclinical myocardial injury as measured using proBNP levels. The converse was also true: participants who experienced a decrease in inflammation had an estimated reduction in CV risk by the RRS as well as a reduction in proBNP levels. These findings are in accordance with current understanding of the role of inflammation in CV risk in RA (2, 18) , as well as in the general population Table 2 for other definitions). † Risk scores were log transformed for calculation of P values. * In the C-reactive protein (CRP) decrease group, n = 68, 65, 70, and 76 for the FRS, the 2013 ACC/AHA, the RRS, and the QRISK, respectively; in the CRP increase group, n = 80, 82, 94, and 96, respectively. Values are the median (interquartile range) 10-year risk as estimated with the given calculator. RA = rheumatoid arthritis (see Table 2 for other definitions). † Risk scores were log transformed for calculation of P values. Table 2 for other definitions). † Risk scores and pro-B-type natriuretic peptide (proBNP) levels were log transformed for calculation of P values. Table 6 . Correlations between change in calculated cardiovascular risk scores and change in proBNP levels in non-statin-treated RA patients with age kept constant (n = 180)* Table 2 for other definitions). † Risk scores and pro-B-type natriuretic peptide (proBNP) levels were log transformed for calculation of P values.
(1). In contrast, no changes in CV risk were observed with the use of the FRS or the 2013 ACC/AHA calculators. The QRISK2 initially showed an increase in risk between the 2 time points regardless of the direction of change in the CRP level. However, this difference was attenuated after controlling for age, suggesting a strong effect of age on CV risk in the QRISK2 calculations.
ProBNP is a marker of cardiac ventricular strain, released from the ventricles in response to increased wall stress (19) . It is also a marker of increased CV risk, with higher levels of proBNP associated with higher CV risk among individuals with and those without existing coronary artery disease (20) . Our data suggest that a change in inflammation had a measurable effect not only on ventricular strain, but potentially on future CV risk. The changes in CV risk were detected with the RRS, the only risk calculator that accounts for some aspect of RA disease activity using CRP levels. Taken together, these data highlight a need to reconsider the strategy for estimating CV risk in individuals who can experience significant changes in inflammation as seen in RA and other inflammatory diseases. Based on a published and internally validated CV risk calculator tailored for RA (18) , accounting for the level of RA disease activity and other clinical factors at baseline improved the accuracy of CV risk estimates.
Previous studies on the accuracy of CV risk estimates in RA have shown that the FRS, RRS, and 2013 ACC/AHA all underestimate CV risk in RA (21) (22) (23) . Additionally, studies have shown that despite moderate estimated CV risk, participants had severe atherosclerotic disease detected using carotid ultrasound and coronary artery calcium scores (24, 25) . With this evidence in mind, we examined a different question, i.e., whether CV risk estimates may change as a result of changes in inflammation. We further investigated whether these changes in inflammation are reflected in a biomarker measuring myocardial strain and CV risk. With most of the CV risk estimators, i.e., the FRS, 2013 ACC/AHA, and QRISK2, the risk did not change significantly with significant changes in inflammation. In contrast, the RRS was sensitive to changes in inflammation, with an increase in inflammation associated with an increase in CV risk. While we acknowledge that risk calculators were not designed to capture changes in CV risk on an annual basis, these results provide evidence that a different approach for CV risk estimation may be needed in RA.
This study highlights a unique characteristic of RA patients compared to the general population: inflammation is of a higher magnitude and can change considerably, leading to higher CV risk with increasing cumulative burden of RA flares (26, 27) . The potential changes in CV risk due to fluctuations in inflammation were reflected by the RRS as well as by a measurement not directly related to CRP levels, proBNP. These changes were not observed with other risk calculators. Follow-up studies in large RA cohorts are needed to validate risk scoring systems that incorporate RA disease activity at baseline (18) and to elucidate the clinical impact of fluctuations in inflammation on future CV risk. Finally, investigators should consider whether a shorter interval of CV risk prediction may be more optimal in RA than the current 10-year predicted risk used for the general population.
The present study also demonstrated significant differences in the estimated CV risk obtained using different calculators. A previous study examined the variation among 16 CV risk calculators and assessed increases in estimated relative risk of CVD with increases in the values or levels of individual risk factors (28) . The weighting of the risk factors varies among calculators, such that a change in one CV risk factor could increase the CV risk estimate obtained using one calculator by 8-fold compared to the estimate obtained using another.
The limitations of our study include the size of the RA cohort and the short follow-up time; it is challenging to assemble and retain an RA cohort with sufficient follow-up time and size to compare estimated CV risk with actual CV outcomes. Thus, we assessed a surrogate marker of CV risk, proBNP levels. Since the goal of the study was to measure changes in CV risk in RA patients in a standardized period of time (1 year), we did not investigate changes before the 1-year period. Additionally, lipid measurements were not performed in the fasting state. However, previous studies have shown that non-fasting total cholesterol and HDL cholesterol levels, used in most calculators, do not differ significantly from those measured in the fasting state (29) . Since this study leveraged data from an observational cohort, there could be differences between the group of participants who experienced an increase in CRP and those who experienced a decrease in CRP. One potential reason for changes in the CRP level is treatment; however, we found no difference in the proportion of patients in the 2 groups who were receiving biologic DMARD therapy (P = 0.997). Additionally, we observed no differences in the magnitude of CRP change between the patients who were receiving biologic DMARD therapy and those who were not, within either the CRP decrease group (P = 0.28) or the CRP increase group (P = 0.89).
In conclusion, among RA patients who experienced a change in CRP level, we found no significant change in CV risk estimates calculated with general populationbased risk calculators with the exception of the RRS. The RRS, which includes CRP as a variable, was sensitive to changes in inflammation, with an increase in inflammation also correlated with evidence of subclinical myocardial stress. This finding, together with evidence that including information on RA clinical factors and disease activity at baseline can improve the accuracy of estimated CV risk, highlights a need to reexamine the general approach to assessing CV risk in RA, toward the use of risk calculators that can incorporate RA-specific factors and potentially, more frequent assessments of CV risk.
